{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:23:49Z","timestamp":1787505829778,"version":"build-2736575974"},"reference-count":26,"publisher":"European Respiratory Society (ERS)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2010,11,30]]},"published-print":{"date-parts":[[2011,7]]},"abstract":"<jats:p>The aim of the present study was to evaluate a 5-yr experience of bosentan in children with pulmonary arterial hypertension (PAH). A retrospective, observational study was made of children in the UK Pulmonary Hypertension Service for Children (Great Ormond Street Hospital for Children, London, UK) who were given bosentan as monotherapy or in combination, from February 2002 to May 2008 and followed up for \u22656 months.<\/jats:p>\n                  <jats:p>Detailed studies were made of 101 children with idiopathic PAH (IPAH) (n = 42) and PAH associated with congenital heart disease (n = 59). Before treatment, World Health Organization (WHO) functional class, 6-min walk distance (6MWD), height, weight and haemodynamic data were determined. Evaluations were analysed after 6 months and annually to a maximum of 5 yrs.<\/jats:p>\n                  <jats:p>Median duration of treatment was 31.5 months. Initial improvement in WHO functional class and 6MWD was maintained for up to 3 yrs. Height and weight increased but the z-scores did not improve. After 3 yrs, bosentan was continued as monotherapy in only 21% of children with IPAH, but in 69% of repaired cases and 56% of those with Eisenmenger syndrome. The Kaplan\u2013Meier survival estimates for the 101 patients were 96, 89, 83 and 60% at 1, 2, 3 and 5 yrs, respectively.<\/jats:p>\n                  <jats:p>A treatment regime that includes bosentan is safe and appears to be effective in slowing disease progression in children with PAH.<\/jats:p>","DOI":"10.1183\/09031936.00053510","type":"journal-article","created":{"date-parts":[[2010,12,22]],"date-time":"2010-12-22T22:29:00Z","timestamp":1293056940000},"page":"70-77","source":"Crossref","is-referenced-by-count":68,"title":["Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children"],"prefix":"10.1183","volume":"38","author":[{"given":"A.A.","family":"Hislop","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Moledina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Schulze-Neick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.G.","family":"Haworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2010,12,22]]},"reference":[{"key":"2024102020314973000_38.1.70.1","doi-asserted-by":"publisher","DOI":"10.1006\/pupt.1998.0126"},{"key":"2024102020314973000_38.1.70.2","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1164\/ajrccm\/148.2.519","article-title":"Circulating immunoreactive endothelin-1 in children with pulmonary hypertension. Association with acute hypoxic pulmonary vasoreactivity","volume":"148","author":"Allen","year":"1993","journal-title":"Am Rev Respir Dis"},{"key":"2024102020314973000_38.1.70.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199306173282402"},{"key":"2024102020314973000_38.1.70.4","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1152\/jappl.1995.79.6.2122","article-title":"Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats","volume":"79","author":"Chen","year":"1995","journal-title":"J Appl Physiol"},{"key":"2024102020314973000_38.1.70.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5223(96)70088-0"},{"key":"2024102020314973000_38.1.70.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06250-X"},{"key":"2024102020314973000_38.1.70.7","doi-asserted-by":"publisher","DOI":"10.1378\/chest.124.1.247"},{"key":"2024102020314973000_38.1.70.8","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi728"},{"key":"2024102020314973000_38.1.70.9","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2006.089185"},{"key":"2024102020314973000_38.1.70.10","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(03)00005-5"},{"key":"2024102020314973000_38.1.70.11","doi-asserted-by":"crossref","unstructured":"Rosenzweig EB Ivy DD Widlitz A . Effects of long-term bosentan in children with pulmonary arterial hypertension. J Am Coll Cardiol 2005 16;46: 697\u2013704.","DOI":"10.1016\/j.jacc.2005.01.066"},{"key":"2024102020314973000_38.1.70.12","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2005.072314"},{"key":"2024102020314973000_38.1.70.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ehj.2004.09.014"},{"issue":"Suppl. 1","key":"2024102020314973000_38.1.70.14","first-page":"I1","article-title":"Recommendations on the management of pulmonary hypertension in clinical practice","volume":"86","year":"2001","journal-title":"Heart"},{"key":"2024102020314973000_38.1.70.15","doi-asserted-by":"publisher","DOI":"10.1136\/adc.73.1.17"},{"key":"2024102020314973000_38.1.70.16","doi-asserted-by":"publisher","DOI":"10.1136\/adc.87.2.104"},{"key":"2024102020314973000_38.1.70.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2006.12.052"},{"key":"2024102020314973000_38.1.70.18","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1203\/PDR.0b013e318179954c","article-title":"Safety experience with bosentan in 146 children 2\u201311 years old with pulmonary arterial hypertension: results from the European Postmarketing Surveillance program","volume":"64","author":"Beghetti","year":"2008","journal-title":"Pediatr Res"},{"key":"2024102020314973000_38.1.70.19","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-005-0266-6"},{"key":"2024102020314973000_38.1.70.20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2009.03532.x"},{"key":"2024102020314973000_38.1.70.21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.2006.01688.x"},{"key":"2024102020314973000_38.1.70.22","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2009.182378"},{"key":"2024102020314973000_38.1.70.23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60919-8"},{"key":"2024102020314973000_38.1.70.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2007.04.078"},{"key":"2024102020314973000_38.1.70.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2007.06.003"},{"key":"2024102020314973000_38.1.70.26","first-page":"510","article-title":"The Swiss registry for pulmonary arterial hypertension: the paediatric experience","volume":"137","author":"Fasnacht","year":"2007","journal-title":"Swiss Med Wkly"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/09031936.00053510","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T01:28:02Z","timestamp":1740360482000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/09031936.00053510"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12,22]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2011,6,30]]},"published-print":{"date-parts":[[2011,7]]}},"alternative-id":["10.1183\/09031936.00053510"],"URL":"https:\/\/doi.org\/10.1183\/09031936.00053510","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12,22]]}}}